{
    "hands_on_practices": [
        {
            "introduction": "The ethical implementation of any diagnostic test requires moving beyond its intrinsic analytical performance to understand its predictive power in a real-world population. The Positive Predictive Value ($PPV$), or the probability that a positive result is a true positive, is profoundly influenced by the prevalence of the condition in the group being tested. This exercise  provides a foundational, hands-on opportunity to calculate the $PPV$ using Bayes' theorem and to confront the \"base-rate effect,\" a common but counterintuitive phenomenon where high-quality tests can yield a large number of false positives in low-prevalence screening scenarios. Mastering this calculation is essential for designing ethical consent, counseling, and confirmatory testing workflows.",
            "id": "5114306",
            "problem": "A public health laboratory plans to deploy a high-throughput molecular screening assay to detect an emergent pathogen in a low-prevalence community cohort. The assay has analytically validated sensitivity $=0.98$ and specificity $=0.95$. The target population prevalence is estimated at $0.005$. Under the ethical, legal, and privacy constraints typical of regulated screening programs in molecular and immunodiagnostics, practitioners must anticipate the rate at which individuals who test positive truly have the condition in order to design consent, counseling, data minimization, and confirmatory testing workflows that meet obligations of respect for persons, beneficence, justice, and confidentiality.\n\nStarting from the formal definitions of sensitivity, specificity, prevalence, and conditional probability, derive an expression for the positive predictive value as a function of these quantities and compute its numerical value for the parameters above. Then, explain why this value arises in low-prevalence screening by carefully connecting to the base-rate effect, and identify at least two ethically salient consequences that bear on (i) the proportionality of screening versus confirmatory testing and (ii) privacy and data governance duties for handling false positives under applicable health privacy regulations.\n\nReport only the positive predictive value as a decimal rounded to four significant figures. Do not use a percent sign. No units are required. Assume one test per person, non-differential test performance across subgroups, and that the prevalence represents the prior probability of disease status in the screened cohort.",
            "solution": "The problem asks for the derivation and calculation of the Positive Predictive Value (PPV) for a molecular screening assay, followed by an analysis of the result in the context of the base-rate effect and its ethical implications.\n\nFirst, let us formalize the provided information using the language of conditional probability. Let $D$ be the event that an individual has the pathogen, and let $\\neg D$ be the event that they do not. Let $T$ be the event of a positive test result, and $\\neg T$ be the event of a negative test result.\n\nThe givens are:\n- The prevalence of the pathogen, which is the prior probability of an individual having the disease: $P(D) = p = 0.005$.\n- The sensitivity of the assay, which is the probability of a positive test given the presence of the disease (the true positive rate): $P(T|D) = \\text{sens} = 0.98$.\n- The specificity of the assay, which is the probability of a negative test given the absence of the disease (the true negative rate): $P(\\neg T|\\neg D) = \\text{spec} = 0.95$.\n\nFrom these givens, we can deduce other relevant probabilities:\n- The probability of an individual not having the disease is $P(\\neg D) = 1 - P(D) = 1 - p = 1 - 0.005 = 0.995$.\n- The false positive rate is the probability of a positive test given the absence of the disease. This is the complement of the specificity: $P(T|\\neg D) = 1 - P(\\neg T|\\neg D) = 1 - \\text{spec} = 1 - 0.95 = 0.05$.\n\nThe quantity to be derived is the Positive Predictive Value (PPV), which is the probability that an individual truly has the disease given that they have received a positive test result. This is the conditional probability $P(D|T)$.\n\nWe use Bayes' theorem to express $P(D|T)$:\n$$P(D|T) = \\frac{P(T|D) P(D)}{P(T)}$$\nThe term in the denominator, $P(T)$, is the total probability of obtaining a positive test result. We can calculate this using the law of total probability, summing over the two possible states of health (having the disease or not):\n$$P(T) = P(T|D)P(D) + P(T|\\neg D)P(\\neg D)$$\nSubstituting the formal definitions for sensitivity, specificity, and prevalence:\n$$P(T) = (\\text{sens}) \\cdot p + (1 - \\text{spec}) \\cdot (1 - p)$$\nNow, we substitute this expression for $P(T)$ back into the formula for Bayes' theorem to obtain the complete expression for the PPV as a function of the given quantities:\n$$PPV = P(D|T) = \\frac{P(T|D) P(D)}{P(T|D)P(D) + P(T|\\neg D)P(\\neg D)}$$\n$$PPV = \\frac{(\\text{sens}) \\cdot p}{(\\text{sens}) \\cdot p + (1 - \\text{spec}) \\cdot (1 - p)}$$\nThis is the derived expression for the positive predictive value.\n\nNow, we compute its numerical value using the provided parameters: $\\text{sens} = 0.98$, $\\text{spec} = 0.95$, and $p = 0.005$.\n$$PPV = \\frac{(0.98) \\cdot (0.005)}{(0.98) \\cdot (0.005) + (1 - 0.95) \\cdot (1 - 0.005)}$$\n$$PPV = \\frac{0.0049}{0.0049 + (0.05) \\cdot (0.995)}$$\n$$PPV = \\frac{0.0049}{0.0049 + 0.04975}$$\n$$PPV = \\frac{0.0049}{0.05465}$$\n$$PPV \\approx 0.089661482159...$$\nRounding to four significant figures as requested, we get $0.08966$.\n\nThe explanation for this strikingly low PPV, where less than $9\\%$ of positive results are correct, lies in the **base-rate effect**. The base rate (prevalence) of the disease is extremely low ($p=0.005$ or $0.5\\%$). To illustrate, consider a cohort of $1,000,000$ individuals.\n- Number of individuals with the disease (true cases): $1,000,000 \\times 0.005 = 5,000$.\n- Number of individuals without the disease (healthy cases): $1,000,000 \\times 0.995 = 995,000$.\nNow, we calculate the number of positive test results:\n- True Positives (diseased individuals who test positive): $5,000 \\times \\text{sens} = 5,000 \\times 0.98 = 4,900$.\n- False Positives (healthy individuals who test positive): $995,000 \\times (1 - \\text{spec}) = 995,000 \\times 0.05 = 49,750$.\nThe total number of positive tests is the sum of these two groups: $4,900 + 49,750 = 54,650$.\nThe PPV is the ratio of true positives to all positives: $\\frac{4,900}{54,650} \\approx 0.08966$.\nThis demonstrates the base-rate effect: even a low false positive rate ($5\\%$) applied to a very large population of healthy individuals generates an absolute number of false positives ($49,750$) that vastly outnumbers the absolute number of true positives ($4,900$) derived from the small population of diseased individuals. The low prevalence is the dominant factor determining the poor predictive power of a single positive test.\n\nThis result has profound ethically salient consequences for the design and implementation of the screening program:\n(i) **Proportionality of screening versus confirmatory testing**: The low PPV makes it ethically imperative to treat a positive screening result not as a diagnosis, but as a trigger for further action. The ethical principle of **beneficence** requires minimizing harm. The potential psychological distress, social stigma, and premature medical intervention based on a likely false positive result constitute significant harms. Therefore, a robust, accessible, and timely confirmatory testing workflow is not merely an adjunct but a central, non-negotiable component of an ethical screening program. The resources for confirmatory testing must be scaled to handle the large number of false positives, not just the number of true cases. The screening test's primary value is in efficiently ruling out disease (its Negative Predictive Value is very high), not in ruling it in.\n\n(ii) **Privacy and data governance duties for handling false positives**: Under health privacy regulations (like HIPAA in the U.S. or GDPR in the E.U.) and the ethical principles of **respect for persons** and **confidentiality**, an individual's health data must be handled with care. A positive test result indicating a specific pathogen is highly sensitive information. Given that over $91\\%$ of these initial positive results are incorrect, their management requires special governance. The principle of **data minimization** dictates that information should be adequate, relevant, and limited to what is necessary. A screening positive result should be recorded as provisional and distinct from a confirmed diagnosis. It must be protected from unauthorized disclosure, especially to entities like insurers or employers, who might act upon this likely-false information to the detriment of the individual. This aligns with the principle of **justice**, ensuring individuals are not unfairly disadvantaged by preliminary and unreliable data. The data governance framework must include clear protocols for amending or deleting a screening result upon receipt of a negative confirmatory test, ensuring the individual's permanent health record accurately reflects their true status.",
            "answer": "$$\n\\boxed{0.08966}\n$$"
        },
        {
            "introduction": "Modern molecular diagnostics has scaled from single-gene tests to large panels and even whole-genome sequencing, where thousands of potential findings are assessed simultaneously. This massive increase in scope presents a unique statistical and ethical challenge: even a test with exceptionally high per-gene specificity can generate a significant cumulative burden of false-positive results across a cohort. This practice  asks you to model and quantify this effect, calculating the expected number of false-positive secondary findings. Such analysis is critical for clinical laboratories to anticipate the downstream demands on genetic counselors and confirmatory testing resources, ensuring that pre-test counseling accurately sets patient expectations about the likelihood of a false alarm.",
            "id": "5114292",
            "problem": "A clinical laboratory offering Whole Genome Sequencing (WGS) returns secondary findings aligned to the American College of Medical Genetics and Genomics (ACMG) actionable gene list during pretest counseling to set expectations about downstream clinical follow-up. For modeling, assume that for each patient, the laboratory renders one binary reportable call per listed gene: “actionable pathogenic variant detected” versus “no actionable pathogenic variant detected.” Analytical validation has established a per-gene call specificity of $s = 0.9995$. The institution’s current actionable list size is $N = 80$ genes. Consider a cohort of $M = 1000$ consecutively consented patients, and, to provide a conservative estimate relevant to counseling burdens, assume all patients are truly negative for reportable pathogenic variants across all $N$ genes.\n\nStarting only from the fundamental definition that specificity is the probability of a true negative result, and the definition of expected value as the average of a random variable over repeated trials, derive an expression for the expected number of false-positive secondary findings across the cohort and then compute its numerical value. You may treat each gene-level call as an independent Bernoulli trial on a truly negative state. Express the final answer as a count (no units) and round your answer to four significant figures.",
            "solution": "The objective is to derive an expression for the expected number of false-positive secondary findings across the given cohort and to compute its numerical value.\n\nPer the problem statement, we begin with the fundamental definition of specificity. Specificity, $s$, is the probability that a test correctly identifies a negative case. In this context, it is the probability of obtaining a \"no actionable pathogenic variant detected\" result for a single gene, given that the patient is truly negative for such a variant in that gene.\n$$s = P(\\text{test negative} | \\text{truly negative})$$\nThe problem specifies that for a single gene, the laboratory renders one of two calls: \"actionable pathogenic variant detected\" or \"no actionable pathogenic variant detected\". Since we are considering a truly negative state, the former outcome corresponds to a false positive ($FP$), and the latter corresponds to a true negative ($TN$). These are the only two possible outcomes for a single test. Therefore, their probabilities must sum to $1$.\n$$P(FP | \\text{truly negative}) + P(TN | \\text{truly negative}) = 1$$\nThe probability of a true negative is the specificity, $s$. The probability of a false positive for a single gene-level test, let us denote it by $p_{fp}$, is thus:\n$$p_{fp} = P(FP | \\text{truly negative}) = 1 - s$$\nThe problem states that each gene-level call is to be treated as an independent Bernoulli trial. For each trial, we define \"success\" as the occurrence of a false-positive finding. Let $X$ be a random variable representing the outcome of a single gene-level test. We can assign $X=1$ for a false positive (success) and $X=0$ for a true negative (failure).\nThe probability of success for this Bernoulli trial is $P(X=1) = p_{fp} = 1-s$.\n\nThe expected value of a single Bernoulli random variable, $E[X]$, is defined as the sum of each possible outcome weighted by its probability.\n$$E[X] = (1 \\cdot P(X=1)) + (0 \\cdot P(X=0)) = P(X=1) = 1-s$$\nThe laboratory performs this test for $N$ genes on each of the $M$ patients. Since each gene-level call is an independent trial, the total number of trials across the entire cohort is the product $N \\times M$.\n\nLet $Y$ be the random variable representing the total number of false-positive findings across the entire cohort. $Y$ is the sum of the outcomes of all $N \\times M$ individual Bernoulli trials. If $X_{ij}$ is the random variable for the test on gene $j$ in patient $i$, then:\n$$Y = \\sum_{i=1}^{M} \\sum_{j=1}^{N} X_{ij}$$\nThe definition of expected value as the average over repeated trials extends to sums of random variables. A fundamental property of expectation is its linearity, which states that the expected value of a sum of random variables is equal to the sum of their individual expected values, regardless of their independence.\n$$E[Y] = E\\left[ \\sum_{i=1}^{M} \\sum_{j=1}^{N} X_{ij} \\right] = \\sum_{i=1}^{M} \\sum_{j=1}^{N} E[X_{ij}]$$\nSince every gene-level test is an identical Bernoulli trial, the expected value for each trial is the same: $E[X_{ij}] = 1-s$. The sum therefore contains $N \\times M$ identical terms.\n$$E[Y] = \\sum_{i=1}^{M} \\sum_{j=1}^{N} (1-s) = M \\cdot N \\cdot (1-s)$$\nThis is the derived expression for the expected number of false-positive secondary findings across the cohort.\n\nWe now substitute the provided numerical values into this expression:\n- Cohort size, $M = 1000$\n- Gene list size, $N = 80$\n- Per-gene call specificity, $s = 0.9995$\n\n$$E[Y] = 1000 \\cdot 80 \\cdot (1 - 0.9995)$$\n$$E[Y] = 1000 \\cdot 80 \\cdot 0.0005$$\n$$E[Y] = 80000 \\cdot 0.0005$$\n$$E[Y] = 8 \\times 10^4 \\cdot 5 \\times 10^{-4}$$\n$$E[Y] = (8 \\cdot 5) \\times (10^4 \\cdot 10^{-4})$$\n$$E[Y] = 40 \\times 10^0 = 40$$\nThe problem requires the answer to be expressed with four significant figures. The exact integer value $40$ must be written as $40.00$ to meet this requirement.",
            "answer": "$$\\boxed{40.00}$$"
        },
        {
            "introduction": "While false positives represent a clear potential for harm, the risk of \"false reassurance\" from a negative result poses a more subtle but equally important ethical concern, especially in the context of direct-to-consumer genetic testing. Many commercial tests use genotyping arrays that only screen for a limited subset of the known pathogenic variants for a given condition. In this exercise , you will calculate the posterior probability that an individual is still a carrier despite receiving a negative test result. This requires integrating principles of population genetics, such as the Hardy-Weinberg equilibrium, with a nuanced application of Bayes' theorem to account for the test's incomplete coverage, providing a crucial lesson in communicating residual risk.",
            "id": "5114300",
            "problem": "A consumer obtains a negative Direct-To-Consumer (DTC) carrier test result for an autosomal recessive condition caused by pathogenic variants in a single gene. In the tested population, the total frequency of all pathogenic alleles for this gene is $q = 0.008$, and the population is in Hardy–Weinberg equilibrium. The test is a genotyping array that targets only specific known variants, with the following scientifically documented spectrum of pathogenic alleles in this ancestry group: a fraction $k = 0.85$ of all pathogenic alleles are known variants, distributed among four categories as follows: variant $V_1$ has proportion $a = 0.50$ of the known spectrum, $V_2$ has $b = 0.25$, $V_3$ has $c = 0.10$, and the aggregate of remaining known rare variants has $d = 0.15$, where $a + b + c + d = 1$. The DTC panel interrogates $V_1$ and $V_2$ only, with analytic sensitivities $s_1 = 0.98$ for $V_1$ and $s_2 = 0.96$ for $V_2$. It does not detect $V_3$, the remaining known rare variants, or any unknown variants. The analytic specificity (true negative rate for non-carriers) is $sp = 0.999$.\n\nAssume carriers are heterozygotes and each carrier’s single pathogenic allele is distributed across the pathogenic spectrum in proportion to the allele fractions described above. The individual has a valid negative test result (neither inconclusive nor a quality failure). Using fundamental definitions that include Hardy–Weinberg equilibrium for carrier frequency in autosomal recessive conditions and Bayes’ theorem for posterior probability, compute the false reassurance risk, defined as the posterior probability $P(\\text{carrier} \\mid \\text{negative})$ in this setting.\n\nExpress your final answer as a decimal and round your answer to four significant figures. No units are required in the final answer.",
            "solution": "The objective is to calculate the false reassurance risk, defined as the posterior probability of an individual being a carrier for an autosomal recessive condition given a negative test result, denoted as $P(\\text{carrier} \\mid \\text{negative})$. Let $C$ represent the event that the individual is a carrier (heterozygous), and $\\text{Neg}$ represent the event that the test result is negative. We seek to compute $P(C \\mid \\text{Neg})$.\n\nAccording to Bayes' theorem, this posterior probability is given by:\n$$P(C \\mid \\text{Neg}) = \\frac{P(\\text{Neg} \\mid C) P(C)}{P(\\text{Neg})}$$\n\nThe denominator, $P(\\text{Neg})$, can be expanded using the law of total probability by conditioning on whether the individual is a carrier or not:\n$$P(\\text{Neg}) = P(\\text{Neg} \\mid C) P(C) + P(\\text{Neg} \\mid \\text{not } C) P(\\text{not } C)$$\n\nTherefore, the full expression for the posterior probability is:\n$$P(C \\mid \\text{Neg}) = \\frac{P(\\text{Neg} \\mid C) P(C)}{P(\\text{Neg} \\mid C) P(C) + P(\\text{Neg} \\mid \\text{not } C) P(\\text{not } C)}$$\n\nWe will compute each term in this expression separately.\n\n**1. Prior Probability of Being a Carrier, $P(C)$**\n\nThe population is in Hardy–Weinberg equilibrium. The total frequency of all pathogenic alleles is given as $q = 0.008$. The frequency of the corresponding normal (wild-type) allele is $p = 1 - q$. The prior probability of an individual being a heterozygous carrier is:\n$$P(C) = 2pq = 2(1-q)q$$\nSubstituting the given value of $q$:\n$$P(C) = 2(1 - 0.008)(0.008) = 2(0.992)(0.008) = 0.015872$$\nThe probability of not being a carrier is the complement:\n$$P(\\text{not } C) = 1 - P(C) = 1 - 0.015872 = 0.984128$$\n\n**2. Conditional Probability of a Negative Result for a Carrier, $P(\\text{Neg} \\mid C)$**\n\nA carrier has one pathogenic allele. The test will be negative if the carrier possesses a pathogenic allele that is not detected by the panel, or if the carrier possesses a detectable allele but the test fails analytically.\n\nThe pathogenic alleles can be categorized as follows:\n- Variants covered by the test: $V_1$ and $V_2$.\n- Variants not covered by the test: $V_3$, other known variants, and unknown variants.\n\nLet's find the probability that a carrier will test positive, $P(\\text{Pos} \\mid C)$. This occurs only if the carrier has variant $V_1$ or $V_2$ AND the test successfully detects it.\nThe problem states that a fraction $k = 0.85$ of all pathogenic alleles are known. The proportions of $V_1$ and $V_2$ within the known spectrum are $a = 0.50$ and $b = 0.25$, respectively.\nThe probability that a carrier's pathogenic allele is $V_1$ is $P(C_{V1} \\mid C) = k \\cdot a$.\nThe probability that a carrier's pathogenic allele is $V_2$ is $P(C_{V2} \\mid C) = k \\cdot b$.\n\nThe analytic sensitivities for these variants are $s_1 = 0.98$ and $s_2 = 0.96$. A positive result for a carrier can only happen for these two variant types.\n$$P(\\text{Pos} \\mid C) = P(\\text{detected} \\mid C_{V1}) P(C_{V1} \\mid C) + P(\\text{detected} \\mid C_{V2}) P(C_{V2} \\mid C)$$\n$$P(\\text{Pos} \\mid C) = s_1 (ka) + s_2 (kb) = k (a s_1 + b s_2)$$\n\nThe probability of a negative result for a carrier is the complement of a positive result:\n$$P(\\text{Neg} \\mid C) = 1 - P(\\text{Pos} \\mid C) = 1 - k(a s_1 + b s_2)$$\nSubstituting the given values:\n$$P(\\text{Neg} \\mid C) = 1 - 0.85 \\left( (0.50)(0.98) + (0.25)(0.96) \\right)$$\n$$P(\\text{Neg} \\mid C) = 1 - 0.85 \\left( 0.49 + 0.24 \\right)$$\n$$P(\\text{Neg} \\mid C) = 1 - 0.85(0.73)$$\n$$P(\\text{Neg} \\mid C) = 1 - 0.6205 = 0.3795$$\n\n**3. Conditional Probability of a Negative Result for a Non-Carrier, $P(\\text{Neg} \\mid \\text{not } C)$**\n\nThe problem provides the analytic specificity as $sp = 0.999$, defined as the true negative rate for non-carriers. Therefore, we use this value directly:\n$$P(\\text{Neg} \\mid \\text{not } C) = sp = 0.999$$\nThis assumes that the group of \"non-carriers\" (which includes homozygous normal $p^2$ and homozygous affected $q^2$ individuals) can be characterized by this single specificity value, a reasonable simplification given that the $p^2$ group constitutes the vast majority of non-carriers ($p^2 \\approx 0.984$, $q^2 \\approx 0.000064$).\n\n**4. Final Calculation of Posterior Probability**\n\nNow we substitute all computed probabilities back into the Bayes' theorem formula:\n$$P(C \\mid \\text{Neg}) = \\frac{P(\\text{Neg} \\mid C) P(C)}{P(\\text{Neg} \\mid C) P(C) + P(\\text{Neg} \\mid \\text{not } C) P(\\text{not } C)}$$\nThe numerator (joint probability of being a carrier and testing negative) is:\n$$P(\\text{Neg and } C) = P(\\text{Neg} \\mid C) P(C) = (0.3795)(0.015872) = 0.006023424$$\nThe denominator (total probability of a negative test) is:\n$$P(\\text{Neg}) = (0.3795)(0.015872) + (0.999)(0.984128)$$\n$$P(\\text{Neg}) = 0.006023424 + 0.983143872 = 0.989167296$$\nFinally, we compute the ratio:\n$$P(C \\mid \\text{Neg}) = \\frac{0.006023424}{0.989167296} \\approx 0.00608935$$\n\nThe problem requires the answer to be rounded to four significant figures. The calculated value is approximately $0.00608935$. The first four significant figures are 6, 0, 8, and 9. Since the next digit is 3, we round down.\n$$P(C \\mid \\text{Neg}) \\approx 0.006089$$\nThis value represents the residual risk of being a carrier despite receiving a negative result from this specific DTC test.",
            "answer": "$$\\boxed{0.006089}$$"
        }
    ]
}